

Giorgio Fassina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8064637/publications.pdf>

Version: 2024-02-01

136
papers

3,283
citations

212478

28
h-index

214428

50
g-index

146
all docs

146
docs citations

146
times ranked

2926
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients. <i>World Journal of Gastroenterology</i> , 2021, 27, 8343-8356.	1.4	1
2	SCCA-IgM as a Potential Biomarker of Non-Alcoholic Fatty Liver Disease in Patients with Obesity, Prediabetes and Diabetes Undergoing Sleeve Gastrectomy. <i>Obesity Facts</i> , 2019, 12, 291-306.	1.6	4
3	Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis. <i>Scientific Reports</i> , 2019, 9, 20126.	1.6	6
4	Characterization of SCCA-IgM as a biomarker of liver disease in an Asian cohort of patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018, 78, 204-210.	0.6	3
5	Development of a novel diagnostic algorithm to predict NASH in HCV-positive patients. <i>International Journal of Biological Markers</i> , 2018, 33, 231-236.	0.7	3
6	Low levels of squamous cell carcinoma antigen-IgM complexes in serum are predictors of better survival in patients with liver cirrhosis. <i>Digestive and Liver Disease</i> , 2018, 50, 42.	0.4	0
7	Clinical evaluation of the iXip index to reduce prostate re-biopsies. <i>Cancer Treatment and Research Communications</i> , 2018, 16, 59-63.	0.7	7
8	Biomarkers development for early detection of cancer: Reducing the burden of cancer in the ageing society. <i>The EuroBiotech Journal</i> , 2018, 2, 30-34.	0.5	1
9	In hepatitis C infected patients with cirrhosis squamous cell carcinoma antigen (SCCA)-IgM levels may contribute to identify the individual risk of hepatocellular carcinoma development after antiviral therapy. <i>Journal of Hepatology</i> , 2017, 66, S212.	1.8	1
10	Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in hepatocellular carcinoma patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2017, 77, 448-453.	0.6	11
11	Clinical validation of the iXip index in avoiding unnecessary prostate biopsy: Results from a prospective multicenter study involving 426 patients. <i>Cancer Treatment and Research Communications</i> , 2017, 10, 40-45.	0.7	5
12	In HCV infected patients with cirrhosis Squamous Cell Carcinoma Antigen (SCCA)-IgM levels may contribute to identify the individual risk of HCC development after antiviral therapy. <i>Digestive and Liver Disease</i> , 2017, 49, e48-e49.	0.4	0
13	P66shc and SerpinB3 interplay affects HCC clinical outcome and cell fate. <i>Digestive and Liver Disease</i> , 2016, 48, e30.	0.4	0
14	SerpinB3 and Yap Interplay Increases Myc Oncogenic Activity. <i>Scientific Reports</i> , 2016, 5, 17701.	1.6	31
15	Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study. <i>Digestive and Liver Disease</i> , 2016, 48, 197-202.	0.4	14
16	P0270 : SerpinB3 and Yap interplay increases Myc oncogenic activity. <i>Journal of Hepatology</i> , 2015, 62, S407-S408.	1.8	0
17	<sc>HCV</sc> genotype 3 and squamous cell carcinoma antigen (<sc>SCCA</sc>)-IgM are independently associated with histological features of <sc>NASH</sc> in <sc>HCV</sc>-infected patients. <i>Journal of Viral Hepatitis</i> , 2015, 22, 800-808.	1.0	12
18	SerpinB3 and Yap interplay increases Myc oncogenic activity. <i>Digestive and Liver Disease</i> , 2015, 47, e31.	0.4	0

#	ARTICLE	IF	CITATIONS
19	A novel algorithm based on serum SCCA-IgM determination combined with common clinical data improves prediction of histological NASH. <i>Digestive and Liver Disease</i> , 2015, 47, e226.	0.4	0
20	Analytical validation of a Biochip prototype for integrated analysis of AFP-IgM and SCCA-IgM serum biomarkers in patients with liver cirrhosis and hepatocellular carcinoma. <i>Analytical Methods</i> , 2015, 7, 629-637.	1.3	5
21	Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C. <i>World Journal of Hepatology</i> , 2015, 7, 2913.	0.8	4
22	The Effects of Combinatorial Chemistry and Technologies on Drug Discovery and Biotechnology â€” a Mini Review. <i>Nova Biotechnologica Et Chimica</i> , 2014, 13, 87-108.	0.1	7
23	SCCA-IgM is predictive of hepatocellular carcinoma development in patients with HCV cirrhosisâ€”A prospective study. <i>Digestive and Liver Disease</i> , 2014, 46, e61.	0.4	0
24	Genotype 3 and circulating SCCA-IgM are independently associated with histological features of NASH in HCV infected patients. <i>Digestive and Liver Disease</i> , 2014, 46, e26.	0.4	0
25	MicroRNAs and SerpinB3 in hepatocellular carcinoma. <i>Life Sciences</i> , 2014, 100, 9-17.	2.0	15
26	Hepatic progenitor cells express SerpinB3. <i>BMC Cell Biology</i> , 2014, 15, 5.	3.0	23
27	SERPINB3 is associated with TGF-Î²1 and cytoplasmic Î²-catenin expression in hepatocellular carcinomas with poor prognosis. <i>British Journal of Cancer</i> , 2014, 110, 2708-2715.	2.9	57
28	Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in HCC patients. <i>Digestive and Liver Disease</i> , 2014, 46, e137.	0.4	0
29	P569 SCCA-IgM IS PREDICTIVE OF HEPATOCELLULAR CARCINOMA DEVELOPMENT IN PATIENTS WITH HCV CIRRHOSIS. A PROSPECTIVE STUDY. <i>Journal of Hepatology</i> , 2014, 60, S259.	1.8	0
30	A novel algorithm for the prediction of prostate cancer in clinically suspected patients. <i>Cancer Biomarkers</i> , 2013, 13, 227-234.	0.8	14
31	Specificity of squamous cell carcinoma antigen (SCCA)â€”IgM detection in patients with HCV infection and rheumatoid factor seropositivity. <i>Journal of Medical Virology</i> , 2013, 85, 1005-1008.	2.5	12
32	SERPINB3 is associated with longer survival in transgenic mice. <i>Scientific Reports</i> , 2013, 3, 3056.	1.6	12
33	SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection. <i>Experimental Biology and Medicine</i> , 2012, 237, 793-802.	1.1	20
34	Biomarkers Quantification with Antibody Arrays in Cancer Early Detection. <i>Clinics in Laboratory Medicine</i> , 2012, 32, 33-45.	0.7	10
35	A screening assay for neuraminidase inhibitors using neuraminidases N1 and N3 from a baculovirus expression system. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2012, 27, 5-11.	2.5	11
36	Over-expression of SERPINB3 in hepatoblastoma: A possible insight into the genesis of this tumour?. <i>European Journal of Cancer</i> , 2012, 48, 1219-1226.	1.3	43

#	ARTICLE	IF	CITATIONS
37	Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 2152-2157.	1.4	16
38	IgM-Linked SerpinB3 and SerpinB4 in Sera of Patients with Chronic Liver Disease. <i>PLoS ONE</i> , 2012, 7, e40658.	1.1	22
39	OC-4 Over-expression of SERPINB3 in hepatoblastoma: A possible insight into the genesis of this tumor?. <i>Digestive and Liver Disease</i> , 2011, 43, S66.	0.4	1
40	T-45 Improved diagnostic accuracy for HCC using a combination of IgM-linked biomarkers. <i>Digestive and Liver Disease</i> , 2011, 43, S91.	0.4	0
41	262 SERPINB3 IS ASSOCIATED TO LONGER SURVIVAL IN MALE TRANSGENIC MICE. <i>Journal of Hepatology</i> , 2011, 54, S108.	1.8	0
42	Structural refinement of protein A mimetic peptide. <i>Journal of Molecular Recognition</i> , 2011, 24, 1087-1094.	1.1	16
43	Increased antiprotease activity of the SERPINB3 polymorphic variant SCCA-PD. <i>Experimental Biology and Medicine</i> , 2011, 236, 281-290.	1.1	17
44	The Quenching Effect of Flavonoids on 4-Methylumbelliferone, a Potential Pitfall in Fluorimetric Neuraminidase Inhibition Assays. <i>Journal of Biomolecular Screening</i> , 2011, 16, 755-764.	2.6	29
45	Solid-phase preparation of protein complexes. <i>Journal of Molecular Recognition</i> , 2010, 23, 551-558.	1.1	3
46	SERPINB3 induces epithelial-mesenchymal transition. <i>Journal of Pathology</i> , 2010, 221, 343-356.	2.1	77
47	Research update for articles published in <i>EJCI</i> in 2008. <i>European Journal of Clinical Investigation</i> , 2010, 40, 770-789.	1.7	1
48	SERPINB3 modulates TGF- β 2 expression in chronic liver disease. <i>Laboratory Investigation</i> , 2010, 90, 1016-1023.	1.7	43
49	Immunity and Cancer: The Role of PSA IgM Immune Complexes for Prostate Cancer. <i>Urologia</i> , 2010, 77, 1-3.	0.3	11
50	Combinatorial Semisynthesis of Biomarker-IgM Complexes. <i>Journal of Biomolecular Screening</i> , 2010, 15, 1274-1280.	2.6	3
51	Experimental validation of specificity of the squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) assay in patients with cirrhosis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 217-23.	1.4	11
52	Role of squamous cell carcinoma antigen-1 on liver cells after partial hepatectomy in transgenic mice. <i>International Journal of Molecular Medicine</i> , 2010, 25, 137-43.	1.8	19
53	SERPINB3, apoptosis and autoimmunity. <i>Autoimmunity Reviews</i> , 2009, 9, 108-112.	2.5	87
54	Structural Characterization of a Protein A Mimetic Peptide Dendrimer Bound to Human IgG. <i>Journal of Physical Chemistry B</i> , 2009, 113, 16268-16275.	1.2	49

#	ARTICLE	IF	CITATIONS
55	Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease. <i>Digestive and Liver Disease</i> , 2009, 41, 212-216.	0.4	10
56	SERPINB3 induces epithelial mesenchymal transition. <i>Digestive and Liver Disease</i> , 2009, 41, A1-A2.	0.4	2
57	Osteopontin-IgM in the diagnosis of HCC. <i>Digestive and Liver Disease</i> , 2009, 41, A4-A5.	0.4	0
58	SCCA-IgM usefulness to monitor patients with cirrhosis is not affected by interfering IgM's. <i>Digestive and Liver Disease</i> , 2009, 41, A11.	0.4	0
59	Combining SCCA-IgM and AFP-IgM levels increases accuracy of hepatocellular carcinoma detection. <i>Digestive and Liver Disease</i> , 2009, 41, A15.	0.4	2
60	Affinity Purification of Immunoglobulins Using Protein A Mimetic (PAM). <i>Springer Protocols</i> , 2009, , 1783-1797.	0.1	0
61	300 SERPINB3 AND TGF- β 1 CORRELATION IN CHRONIC LIVER DISEASE. <i>Journal of Hepatology</i> , 2009, 50, S117.	1.8	0
62	Role of squamous cell carcinoma antigen-1 on liver cells after partial hepatectomy in transgenic mice. <i>International Journal of Molecular Medicine</i> , 2009, 25, .	1.8	6
63	Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , 2008, 38, 571-577.	1.7	27
64	Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis. <i>Journal of Viral Hepatitis</i> , 2008, 15, 246-249.	1.0	35
65	[471] SQUAMOUS CELL CARCINOMA ANTIGEN (SCCA) EXPRESSION AND CD27+ MEMORY B LYMPHOCYTES IN PATIENTS WITH CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2007, 46, S179.	1.8	1
66	Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients. <i>Cancer Detection and Prevention</i> , 2007, 31, 402-407.	2.1	37
67	Expression pattern of squamous cell carcinoma antigen in oesophageal dysplasia and squamous cell carcinoma. <i>Histology and Histopathology</i> , 2007, 22, 989-95.	0.5	6
68	240 Des-gamma-carboxy prothrombin-IgM immune complex as novel biomarker for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2006, 44, S96-S97.	1.8	0
69	241 Improvement of sensitivity for liver cancer detection by simultaneous evaluation of SCCA-IgM, AFP-IgM complexes and free AFP. <i>Journal of Hepatology</i> , 2006, 44, S97.	1.8	0
70	271 Monitoring SCCA-IGM complex predicts HCC development in cirrhotic patients. <i>Journal of Hepatology</i> , 2006, 44, S107.	1.8	0
71	Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2006, 119, 735-740.	2.3	73
72	Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. <i>Cancer</i> , 2005, 103, 2558-2565.	2.0	118

#	ARTICLE	IF	CITATIONS
73	Detection of Circulating CEA-IgM Complexes in Early Stage Colorectal Cancer. International Journal of Biological Markers, 2005, 20, 204-208.	0.7	34
74	Sequence specific peptidomimetic molecules inhibitors of a protein-protein interaction at the helix 1 level of c-Myc. FASEB Journal, 2005, 19, 1-26.	0.2	23
75	Improvement of Liver Cancer Detection with Simultaneous Assessment of Circulating Levels of Free Alpha-Fetoprotein (AFP) and Afp-Igm Complexes. International Journal of Biological Markers, 2004, 19, 155-159.	0.7	46
76	Constitutive membrane expression of proteinase 3 (PR3) and neutrophil activation by anti-PR3 antibodies. Journal of Leukocyte Biology, 2004, 76, 1162-1170.	1.5	40
77	Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma. British Journal of Cancer, 2004, 90, 833-837.	2.9	114
78	244 Serological detection of squamous cell carcinoma antigen-IGM complexes in hepatocellular carcinoma. Journal of Hepatology, 2004, 40, 77.	1.8	0
79	Surface expression of squamous cell carcinoma antigen (SCCA) can be increased by the preS1(21-47) sequence of hepatitis B virus. Journal of General Virology, 2004, 85, 621-624.	1.3	8
80	Fcγ3RIIIb Allele-Sensitive Release of α-Defensins: Anti-Neutrophil Cytoplasmic Antibody-Induced Release of Chemotaxins. Journal of Immunology, 2003, 171, 6090-6096.	0.4	27
81	Surface expression of squamous cell carcinoma antigen (SCCA) variant can be upregulated by pre-S1(21-47) sequence of HBV. Journal of Hepatology, 2002, 36, 83.	1.8	0
82	Sequence-simplification and chimeric assembly: new models of peptide antigen modification. Molecular Immunology, 2002, 39, 443-451.	1.0	4
83	Novel Molecular Targets for Systemic Lupus Erythematosus. Current Drug Targets, 2002, 3, 223-8.	1.0	4
84	N-terminal myristoylation of HBV Pre-S1 domain affects folding and receptor recognition. , 2002, , 537-538.		0
85	Cross-immunogenicity of topological mimics of peptide antigens. , 2002, , 773-774.		0
86	Novel ligands for the affinity-chromatographic purification of antibodies. Journal of Proteomics, 2001, 49, 481-490.	2.4	119
87	N-terminal myristylation of HBV preS1 domain enhances receptor recognition. Chemical Biology and Drug Design, 2001, 57, 390-400.	1.2	26
88	Cloning and Expression of a Novel Hepatitis B Virus-binding Protein from HepG2 Cells. Journal of Biological Chemistry, 2001, 276, 36613-36623.	1.6	69
89	Affinity purification of immunoglobulins from chicken egg yolk using a new synthetic ligand. Biomedical Applications, 2000, 749, 233-242.	1.7	77
90	Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide. Nature Biotechnology, 2000, 18, 735-739.	9.4	62

#	ARTICLE	IF	CITATIONS
91	De Novo Design of Peptides Targeted to the EF Hands of Calmodulin. Journal of Biological Chemistry, 2000, 275, 2676-2685.	1.6	53
92	Prevention of experimental autoimmune encephalomyelitis by encephalitogenic epitope sequence simplified derivatives. Molecular Immunology, 2000, 37, 951-960.	1.0	5
93	Protein A Mimetic (PAM) Affinity Chromatography. Methods in Molecular Biology, 2000, 147, 57-68.	0.4	9
94	Inhibition of experimental autoimmune encephalomyelitis in SJL mice by oral administration of retro-inverso derivative of encephalitogenic epitope P87. European Journal of Immunology, 1999, 29, 2560-2566.	1.6	15
95	Inhibition of experimental autoimmune encephalomyelitis in SJL mice by oral administration of retro-inverso derivative of encephalitogenic epitope P87. , 1999, 29, 2560.		2
96	IRIS 97: an innovative protein A-peptidomimetic solid phase medium for antibody purification. , 1998, 11, 107-109.		23
97	Immunoglobulin specificity of TG19318: a novel synthetic ligand for antibody affinity purification. , 1998, 11, 128-133.		113
98	A synthetic ligand for IgA affinity purification. , 1998, 11, 243-246.		44
99	Affinity purification of mouse monoclonal IgE using a protein A mimetic ligand (TG19318) immobilized on solid supports. , 1998, 11, 247-249.		51
100	Affinity purification of immunoglobulin M using a novel synthetic ligand. Biomedical Applications, 1998, 715, 137-145.	1.7	54
101	Secretion of Thiols and Disulfide Bond Formation: Retraction. Science, 1998, 279, 1283j-1283.	6.0	2
102	Cysteine and Glutathione Secretion in Response to Protein Disulfide Bond Formation in the ER. Science, 1997, 277, 1681-1684.	6.0	93
103	Effect of bench-scale culture conditions on murine IgG heterogeneity. , 1997, 54, 17-25.		11
104	An Expression System for the Single-Step Production of Recombinant Human Amidated Calcitonin. Protein Expression and Purification, 1996, 7, 347-354.	0.6	11
105	Formation of reversible disulfide bonds with the protein matrix of the endoplasmic reticulum correlates with the retention of unassembled Ig light chains.. EMBO Journal, 1996, 15, 2077-2085.	3.5	101
106	Protein a mimetic peptide ligand for affinity purification of antibodies. , 1996, 9, 564-569.		114
107	Peptide immobilization on calcium alginate beads: applications to antibody purification and assay. Biomedical Applications, 1995, 664, 127-135.	1.7	12
108	Affinity purification of polyclonal antibodies using immobilized multimeric peptides. Biomedical Applications, 1995, 664, 175-183.	1.7	18

#	ARTICLE	IF	CITATIONS
109	Antigenicity of topochemically related peptides. BBA - Proteins and Proteomics, 1995, 1253, 57-62.	2.1	10
110	Topological Mimicry of Cross-reacting Enantiomeric Peptide Antigens. Journal of Biological Chemistry, 1995, 270, 30422-30427.	1.6	30
111	Inhibition of Interleukin-2/p55 Receptor Subunit Interaction by Complementary Peptides. Archives of Biochemistry and Biophysics, 1995, 318, 37-45.	1.4	16
112	Binding of the LXCXE Insulin Motif to a Hexapeptide Derived from Retinoblastoma Protein. Biochemical and Biophysical Research Communications, 1995, 206, 97-102.	1.0	24
113	Endo-group modified <i>retro</i> isomers of tripeptide oxytocin analogues: binding to neurophysin II and enhancement of its self-association properties. International Journal of Peptide and Protein Research, 1995, 45, 356-365.	0.1	12
114	Complementary Peptides as Recognition Molecules. , 1995, 46, 109-120.		3
115	High Yield Expression and Purification of Human Endothelin-1. Protein Expression and Purification, 1994, 5, 559-568.	0.6	4
116	Identification of Interactive Sites of Proteins and Protein Receptors by Computer-Assisted Searches for Complementary Peptide Sequences. ImmunoMethods, 1994, 5, 114-120.	0.8	7
117	Complementary Peptides as Antibody Mimetics for Protein Purification and Assay. ImmunoMethods, 1994, 5, 121-129.	0.8	5
118	Binding of Type I IL-1 ^{Î²} Receptor Fragment 151-162 to Interleukin-1 ^{Î²} . Growth Factors, 1994, 10, 99-106.	0.5	3
119	Facile Manual Synthesis of Peptide Libraries. Protein and Peptide Letters, 1994, 1, 187-192.	0.4	5
120	Peptides sandwich assay for interleukin-2 detection. , 1993, , 907-908.		2
121	Design and recognition properties of a hydrophatically complementary peptide to human interleukin 1 ^{Î²} . Biochemical Journal, 1992, 282, 773-779.	1.7	23
122	Oligomeric tumour necrosis factor ^{Î±} slowly converts into inactive forms at bioactive levels. Biochemical Journal, 1992, 284, 905-910.	1.7	117
123	Antigenic regions of tumor necrosis factor alpha and their topographic relationships with structural/functional domains. Molecular Immunology, 1992, 29, 471-479.	1.0	8
124	Binding of human tumor necrosis factor ^{Î±} to multimeric complementary peptides. Archives of Biochemistry and Biophysics, 1992, 296, 137-143.	1.4	26
125	Oriented immobilization of peptide ligands on solid supports. Journal of Chromatography A, 1992, 591, 99-106.	1.8	27
126	Design of hydrophatically complementary peptides for Big Endothelin affinity purification. International Journal of Peptide and Protein Research, 1992, 39, 540-548.	0.1	18

#	ARTICLE	IF	CITATIONS
127	Affinity enhancement of complementary peptide recognition. International Journal of Peptide and Protein Research, 1992, 39, 549-556.	0.1	22
128	Mobile phase effects in the high-performance affinity purification of thermolysin. Journal of Chromatography A, 1991, 549, 195-205.	1.8	3
129	Sequence simplification and the intra- and intermolecular self-recognition properties of vasopressin/neurophysin biosynthetic precursor. Journal of Molecular Recognition, 1989, 1, 158-165.	1.1	2
130	Recognition properties of antisense peptides to Arg8-vasopressin/bovine neurophysin II biosynthetic precursor sequences. Biochemistry, 1989, 28, 8811-8818.	1.2	34
131	Sequence Directed Design of Recognition Peptides. , 1989, , 431-438.		5
132	Screening the recognition properties of peptide hormone sequence mutants by analytical high performance liquid affinity chromatography on immobilized neurophysin. Collection of Czechoslovak Chemical Communications, 1988, 53, 2627-2636.	1.0	6
133	Molecular diagnostics using analytical immuno high performance liquid affinity chromatography. Applied Biochemistry and Biotechnology, 1987, 16, 119-128.	1.4	4
134	Correlation between sites of limited proteolysis and segmental mobility in thermolysin. Biochemistry, 1986, 25, 1847-1851.	1.2	315
135	Quantitative high-performance affinity chromatography: Evaluation of use for analyzing peptide and protein interactions. Biomedical Applications, 1986, 376, 87-93.	1.7	20
136	Autolysis of thermolysin. Isolation and characterization of a folded three-fragment complex. FEBS Journal, 1986, 156, 221-228.	0.2	41